<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8F5430F8-D819-4EE8-9D2B-513E701178AF"><gtr:id>8F5430F8-D819-4EE8-9D2B-513E701178AF</gtr:id><gtr:name>Immune Design</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7177D8AC-2686-4D94-816A-10D52DA60ADB"><gtr:id>7177D8AC-2686-4D94-816A-10D52DA60ADB</gtr:id><gtr:name>Kenya AIDS Vaccine Initiative (KAVI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/60F248FE-C8E5-4717-901F-B0303E223FF9"><gtr:id>60F248FE-C8E5-4717-901F-B0303E223FF9</gtr:id><gtr:name>Huntingdon Life Sciences</gtr:name><gtr:address><gtr:line1>Huntingdon Life Sciences</gtr:line1><gtr:line2>Woolley Road</gtr:line2><gtr:line3>Alconbury</gtr:line3><gtr:postCode>PE28 4HS</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ED9688EB-63CD-48F5-8C4C-1C812B0955AD"><gtr:id>ED9688EB-63CD-48F5-8C4C-1C812B0955AD</gtr:id><gtr:name>MediTox s.r.o.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3348FD29-79EB-47C2-9639-489D9C4E5DEE"><gtr:id>3348FD29-79EB-47C2-9639-489D9C4E5DEE</gtr:id><gtr:name>Los Alamos National Laboratory</gtr:name><gtr:address><gtr:line1>Los Alamos National Laboratory</gtr:line1><gtr:line2>PO Box 1663</gtr:line2><gtr:line3>Los Alamos</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE"><gtr:id>1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE</gtr:id><gtr:name>IrsiCaixa Institute for AIDS Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/22F01640-ABE4-47E4-AD36-61CB99D205A4"><gtr:id>22F01640-ABE4-47E4-AD36-61CB99D205A4</gtr:id><gtr:name>Cellectis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2"><gtr:id>65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2</gtr:id><gtr:name>Cornell University</gtr:name><gtr:address><gtr:line1>410 Thurston Ave</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DFE6B693-9C12-4961-8B35-A4F7346A202A"><gtr:id>DFE6B693-9C12-4961-8B35-A4F7346A202A</gtr:id><gtr:name>Recipharm</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/70713789-B41C-4730-A26D-B92DD613858D"><gtr:id>70713789-B41C-4730-A26D-B92DD613858D</gtr:id><gtr:name>IDT Biologika GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CBCD41ED-035C-40C2-BD4E-17CC8D2DB4AB"><gtr:id>CBCD41ED-035C-40C2-BD4E-17CC8D2DB4AB</gtr:id><gtr:name>HIV Vaccine Trials Network, USA</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30326D2E-953D-4CE9-9350-309A797BD01C"><gtr:id>30326D2E-953D-4CE9-9350-309A797BD01C</gtr:id><gtr:name>HIVACAT Program IrsiCaixa Institute for AIDS Research</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Experimental Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8F5430F8-D819-4EE8-9D2B-513E701178AF"><gtr:id>8F5430F8-D819-4EE8-9D2B-513E701178AF</gtr:id><gtr:name>Immune Design</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7177D8AC-2686-4D94-816A-10D52DA60ADB"><gtr:id>7177D8AC-2686-4D94-816A-10D52DA60ADB</gtr:id><gtr:name>Kenya AIDS Vaccine Initiative (KAVI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/60F248FE-C8E5-4717-901F-B0303E223FF9"><gtr:id>60F248FE-C8E5-4717-901F-B0303E223FF9</gtr:id><gtr:name>Huntingdon Life Sciences</gtr:name><gtr:address><gtr:line1>Huntingdon Life Sciences</gtr:line1><gtr:line2>Woolley Road</gtr:line2><gtr:line3>Alconbury</gtr:line3><gtr:postCode>PE28 4HS</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ED9688EB-63CD-48F5-8C4C-1C812B0955AD"><gtr:id>ED9688EB-63CD-48F5-8C4C-1C812B0955AD</gtr:id><gtr:name>MediTox s.r.o.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3348FD29-79EB-47C2-9639-489D9C4E5DEE"><gtr:id>3348FD29-79EB-47C2-9639-489D9C4E5DEE</gtr:id><gtr:name>Los Alamos National Laboratory</gtr:name><gtr:address><gtr:line1>Los Alamos National Laboratory</gtr:line1><gtr:line2>PO Box 1663</gtr:line2><gtr:line3>Los Alamos</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE"><gtr:id>1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE</gtr:id><gtr:name>IrsiCaixa Institute for AIDS Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/22F01640-ABE4-47E4-AD36-61CB99D205A4"><gtr:id>22F01640-ABE4-47E4-AD36-61CB99D205A4</gtr:id><gtr:name>Cellectis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2"><gtr:id>65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2</gtr:id><gtr:name>Cornell University</gtr:name><gtr:address><gtr:line1>410 Thurston Ave</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DFE6B693-9C12-4961-8B35-A4F7346A202A"><gtr:id>DFE6B693-9C12-4961-8B35-A4F7346A202A</gtr:id><gtr:name>Recipharm</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/70713789-B41C-4730-A26D-B92DD613858D"><gtr:id>70713789-B41C-4730-A26D-B92DD613858D</gtr:id><gtr:name>IDT Biologika GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CBCD41ED-035C-40C2-BD4E-17CC8D2DB4AB"><gtr:id>CBCD41ED-035C-40C2-BD4E-17CC8D2DB4AB</gtr:id><gtr:name>HIV Vaccine Trials Network, USA</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30326D2E-953D-4CE9-9350-309A797BD01C"><gtr:id>30326D2E-953D-4CE9-9350-309A797BD01C</gtr:id><gtr:name>HIVACAT Program IrsiCaixa Institute for AIDS Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8B063DF8-CBFF-4B1C-BE0C-60F2F7CF71D8"><gtr:id>8B063DF8-CBFF-4B1C-BE0C-60F2F7CF71D8</gtr:id><gtr:firstName>Tomas</gtr:firstName><gtr:surname>Hanke</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6D3EDEF4-896A-4E6D-9ACD-25FE64728AA2"><gtr:id>6D3EDEF4-896A-4E6D-9ACD-25FE64728AA2</gtr:id><gtr:firstName>Lucy</gtr:firstName><gtr:surname>Dorrell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701669"><gtr:id>718D829F-A5CD-4B6E-86CB-929A542B5FB7</gtr:id><gtr:title>Development of a universal HIV-1 vaccine</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701669</gtr:grantReference><gtr:abstractText>HIV infection and AIDS continues to spread in a virtually uncontrolled manner. The best and possibly only hope to change this alarming situation is a safe, effective, accessible protective vaccine. Arguably the biggest challenge in developing such a vaccine is the enormous HIV variability, which dwarfs almost any other infection. However, all parts of the virus cannot easily change. To remain alive, HIV has to keep some smaller regions of its proteins more or less constant. We have taken an advantage of this and constructed a simple candidate vaccine designed specifically to overcome the HIV variability by focusing the body defences on the conserved viral parts. Here, we are proposing to test this approach for the first time in a small pilot study in healthy individuals in Oxford. Successful outcome of this study would strongly support further evaluation of this vaccination strategy in larger and more expensive clinical studies.</gtr:abstractText><gtr:technicalSummary>This proposal will test for the first time in humans several novel, state-of-the-art technologies combined to provide maximum benefit to vaccinated individuals. First, one of the big roadblocks in development of HIV-1/AIDS vaccines is the enormous diversity of HIV-1, which could limit the value of any HIV-1 vaccine candidate currently under test. To address the HIV-1 variation, we designed a novel T cell immunogen, designated HIVconsv, by assembling the 14 most conserved regions of the HIV-1 proteome into one chimaeric protein. Each segment is a consensus sequence from one of the four major HIV-1 clades A, B, C and D, which alternate to ensure equal clade coverage. We demonstrated that these conserved regions prime CD8+ and CD4+ T cell to highly conserved epitopes in patients during natural HIV-1 infection and that these epitopes, although usually subdominant, generate memory T cells. Here, we propose to test the immunogenicity of the HIVconsv chimearic protein in a pilot small phase I trial in healthy HIV-1-uninfected individuals in Oxford to assess the breadth, specificity and cross-clade reactivity of the vaccine induced T cells. Second, we shall deliver the HIVconsv gene in a novel vaccine vector based on adenovirus of chimpanzee origin (AdC), which matches and possibly outperforms the currently perceived most immunogenic vaccine vector, human Adenovirus serotype 5 (AdHu5). Third, we shall use the AdC.HIVconsv vaccine in a heterologous prime-boost regimen of DNA/AdC/modified vaccinia virus Ankara (MVA) to further increase the vaccination potency. The HIVconsv-induced T cell responses will be assessed in a comprehensive analysis of frequency, phenotype and functionality, which will indicate according to pre-determined stringent criteria whether or not our vaccine strategy should advance to a larger proof-of-principle trial. In summary, our vaccination approach provides an attractive and testable alternative for overcoming the HIV-1 variability, while focusing T cell responses on regions of the virus that are less likely to mutate and escape. Furthermore, it has merit in the simplicity of design and delivery, requiring only a single immunogen to provide extensive coverage of global HIV-1 population diversity.</gtr:technicalSummary><gtr:fund><gtr:end>2012-10-27</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-28</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1300519</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Induction of HIV neutralizing antibodies</gtr:description><gtr:id>576E4279-8672-4F0F-8904-6D2810DB278C</gtr:id><gtr:impact>Studies with BG505 uncleaved - Publication

Studies with BG505 SOSIP - In progress</gtr:impact><gtr:outcomeId>54620bc661cd03.33177083-2</gtr:outcomeId><gtr:partnerContribution>WCMC - provision or trimeric gp140 BG505 SOSIP protein immunogen
IAVI - proviion of gp120 HBG505 unlceaved immunogen
Sir Willima Dunn Schol of Pathology - quality control and research assays for characterisation of vector-expressed Ev immunogen
Meditox - rabbit immunization study</gtr:partnerContribution><gtr:piContribution>We are developing heterologous prime-boost immunisation regimen delivering a highly promising HIV Env BG505 uncleaved or as SOSIP for induction of HIV neutralising antibodies.

Also we are developing regimens for efficient induction of T cell and B cell responses in parallel.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cellectis</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Cyto Pulse</gtr:department><gtr:description>DNA electroporation</gtr:description><gtr:id>9D3D5205-4462-4DB8-B61A-C67949845F1D</gtr:id><gtr:impact>T cell immunogenicity of electroporated DNA alone and in combination with other vaccine modalities in mice and non-human primates are on-going</gtr:impact><gtr:outcomeId>B65E840D2A7-1</gtr:outcomeId><gtr:partnerContribution>Expertise and instrument for DNA electroporation</gtr:partnerContribution><gtr:piContribution>Immunogenicity of electroporated DNA</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Huntingdon Life Sciences</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Pre-clinical toxicology</gtr:description><gtr:id>30862EE8-06FD-4680-AAB2-1FD8E6A9058D</gtr:id><gtr:impact>Two toxicology studies UNO0011 (MVA.HIVconsv) and UNO0012 (pSG2.HIVconsv and ChAdV63.HIVconsv), which support the MHRA applications to trials HIV-CORE001 and HIV-CORE002 have now been completed.</gtr:impact><gtr:outcomeId>14BA3F17AD0-1</gtr:outcomeId><gtr:partnerContribution>Expertise in pre-clinical toxicology</gtr:partnerContribution><gtr:piContribution>Pre-clinical toxicology in mice</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Determination of binding affinities of peptides for HLA</gtr:description><gtr:id>84881C2D-F872-4817-973F-07FE59154EF6</gtr:id><gtr:impact>Manuscript in preparation</gtr:impact><gtr:outcomeId>54621498ddaab0.75804935-1</gtr:outcomeId><gtr:partnerContribution>HLA affinity assay</gtr:partnerContribution><gtr:piContribution>Peptide identification and provision</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Human Immunology Laboratory, ICL</gtr:department><gtr:description>Sample evaluation in HIL reference laboratory</gtr:description><gtr:id>F09A8D14-4CE3-4D47-9104-79F3F284438E</gtr:id><gtr:impact>The results will likely be part of publication describing immunogenicity of the HIVconsv vaccines tested in HIV-CORE002. Comparative data with other vaccine strategies.</gtr:impact><gtr:outcomeId>Rap6cab2iHY-1</gtr:outcomeId><gtr:partnerContribution>IFN-y ELISPOT assays comparative with other HIV vaccine candidates tested by IAVI and others</gtr:partnerContribution><gtr:piContribution>Frozen PBMC samples from clinical trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Immune Design</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Construction and testing of Retrovirus-vectored tHIVconsvX vaccines</gtr:description><gtr:id>CBA4CF7F-2A95-415F-A3DB-431D512BBEFB</gtr:id><gtr:impact>In progress</gtr:impact><gtr:outcomeId>54620ddf7ba591.76223835-1</gtr:outcomeId><gtr:partnerContribution>Construction of two candidate vaccines.</gtr:partnerContribution><gtr:piContribution>Provision of 2 tHIVconsvX genes and preclinical testing of candidate vaccines.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Los Alamos National Laboratory</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Development of a conserved mosaic protein as an immunogen</gtr:description><gtr:id>D996135A-389F-44B8-A604-55FC7B3E88D9</gtr:id><gtr:impact>Early days</gtr:impact><gtr:outcomeId>ArZ75UzU9Wd-1</gtr:outcomeId><gtr:partnerContribution>Providing an expertise in designing a vaccine immunogen</gtr:partnerContribution><gtr:piContribution>We describe what immunogen we would like to design and LANL used their computational power to design this immunogen. We then construct it and develop it</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Sciences</gtr:department><gtr:description>GMP manufacture of pSG2.HIVconsv DNA/QP release</gtr:description><gtr:id>EB6B1D1A-37ED-4E69-8D56-475EA6525ED2</gtr:id><gtr:impact>GMP batch of plasmid DNA has been completed</gtr:impact><gtr:outcomeId>C43A7427319-1</gtr:outcomeId><gtr:partnerContribution>Expertise in GMP manufacture of plasmid DNA vaccine pSG2.HIVconsv QP release to GMP and clinical trial</gtr:partnerContribution><gtr:piContribution>GMP manufacture and QP release of clinical batch of plasmid DNA</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Sir William Dunn School of Pathology</gtr:department><gtr:description>Induction of HIV neutralizing antibodies</gtr:description><gtr:id>53BD3D18-FDFE-4574-BCC8-3BE07FAF24A4</gtr:id><gtr:impact>Studies with BG505 uncleaved - Publication

Studies with BG505 SOSIP - In progress</gtr:impact><gtr:outcomeId>54620bc661cd03.33177083-3</gtr:outcomeId><gtr:partnerContribution>WCMC - provision or trimeric gp140 BG505 SOSIP protein immunogen
IAVI - proviion of gp120 HBG505 unlceaved immunogen
Sir Willima Dunn Schol of Pathology - quality control and research assays for characterisation of vector-expressed Ev immunogen
Meditox - rabbit immunization study</gtr:partnerContribution><gtr:piContribution>We are developing heterologous prime-boost immunisation regimen delivering a highly promising HIV Env BG505 uncleaved or as SOSIP for induction of HIV neutralising antibodies.

Also we are developing regimens for efficient induction of T cell and B cell responses in parallel.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Clinical evaluation of ChAdV63.HIVconsv</gtr:description><gtr:id>33F6A6E3-468D-438A-8B11-C2F8857C1BF2</gtr:id><gtr:impact>In process.</gtr:impact><gtr:outcomeId>546204216bbd14.60992852-1</gtr:outcomeId><gtr:partnerContribution>The GSK partner added a very slow and cumbersome process of approving of the jointly owned candidate vaccine for use in clinical trials. GSK is not interested in an early stage development of HIV vaccines.</gtr:partnerContribution><gtr:piContribution>GSK acquired Okairos, the developer of the ChAdV-63-based vector platform. We are testing the ChAdV63.HIVconsv in four clinical trials: RIVER, PEACHI 04, HIV-CORE 003 and BCN 01.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>HIV Vaccine Trials Network, USA</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Sample evaluation at HVTN</gtr:description><gtr:id>529DFD09-AF6E-4293-9C05-2FCF4DBD167E</gtr:id><gtr:impact>Comparative data with other vaccine strategies.</gtr:impact><gtr:outcomeId>ZFzUPPnVosS-1</gtr:outcomeId><gtr:partnerContribution>Know-how, evaluation of samples in standardized, reference assays.</gtr:partnerContribution><gtr:piContribution>We have provided samples from clinical trial HIV-CORE002 and peptides.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cornell University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Weill Cornell Medicine</gtr:department><gtr:description>Antibody Vaccine Development</gtr:description><gtr:id>4056A07A-34DA-4BB4-B343-C39BB5C35870</gtr:id><gtr:impact>Vaccines under construction</gtr:impact><gtr:outcomeId>RqdnTmjpfPM-1</gtr:outcomeId><gtr:partnerContribution>Immunogen BG505 SOSIP
Structural characterization of expressed proteins</gtr:partnerContribution><gtr:piContribution>Construction of new vaccines
Pre-clinical immunogenicity
Optimizing co-delivery of Ab and T cell vaccines</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>HIVACAT Program IrsiCaixa Institute for AIDS Research</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Construction of MVA.HIVACAT-T for pre-clinical and clinical testing</gtr:description><gtr:id>2E015D56-431C-460D-A400-FCE8BBD8D9C5</gtr:id><gtr:impact>Publication submitted</gtr:impact><gtr:outcomeId>54620cf2cabc24.96454045-1</gtr:outcomeId><gtr:partnerContribution>Design of HIVACAT-T immunogen, preclinical testing in mice and monkeys.

GMP manufacture</gtr:partnerContribution><gtr:piContribution>Construction of candidate HIV vaccine MVA.HIVACAT-T carrying a IRSICAIXA-designed T cell immunogen

Advice on GMP manufacture</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MediTox s.r.o.</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>Induction of HIV neutralizing antibodies</gtr:description><gtr:id>DBABD1C0-6FB9-43ED-AB36-D5A283DD01A1</gtr:id><gtr:impact>Studies with BG505 uncleaved - Publication

Studies with BG505 SOSIP - In progress</gtr:impact><gtr:outcomeId>54620bc661cd03.33177083-4</gtr:outcomeId><gtr:partnerContribution>WCMC - provision or trimeric gp140 BG505 SOSIP protein immunogen
IAVI - proviion of gp120 HBG505 unlceaved immunogen
Sir Willima Dunn Schol of Pathology - quality control and research assays for characterisation of vector-expressed Ev immunogen
Meditox - rabbit immunization study</gtr:partnerContribution><gtr:piContribution>We are developing heterologous prime-boost immunisation regimen delivering a highly promising HIV Env BG505 uncleaved or as SOSIP for induction of HIV neutralising antibodies.

Also we are developing regimens for efficient induction of T cell and B cell responses in parallel.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Human Immunology Laboratory, ICL</gtr:department><gtr:description>HIV inhibition assays</gtr:description><gtr:id>95571119-222F-43AE-86EF-AFDC1F489B69</gtr:id><gtr:impact>Assays are in progress.</gtr:impact><gtr:outcomeId>WF5jfYE8Ssq-1</gtr:outcomeId><gtr:partnerContribution>International AIDS Vaccine Initiative provide the expertise in VIA, welcome our student and provided HIV virus stock of various clades</gtr:partnerContribution><gtr:piContribution>We provide samples from clinical trial, a visiting DPhil student and contribute to the cost of the virus inhibition assay (VIA)</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>HIVACAT Program IrsiCaixa Institute for AIDS Research</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Clinical trial BCN01 in Barcelona</gtr:description><gtr:id>91C9BCD1-41E3-4CE8-B6B6-0877CADB6ACE</gtr:id><gtr:impact>Trial approved, recruitment started.</gtr:impact><gtr:outcomeId>RQw6grjmf6k-1</gtr:outcomeId><gtr:partnerContribution>Cohort of patients identified during AHI, antiretrovirals drugs, running the trial and primary immunological assays.</gtr:partnerContribution><gtr:piContribution>Providing knowhow, GMP vaccines and some reagents for a clinical trial BCN01 testing immunogenicity of HIVconsv vaccines in newly-infected patients treated with antiretrovirals within the first 6 months of infection.</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>IAVI-replication-competent virus vectors</gtr:description><gtr:id>553B69C0-7170-482F-9B85-92012C6094F9</gtr:id><gtr:impact>vector are being constructed</gtr:impact><gtr:outcomeId>tPP6GsAZSH2-1</gtr:outcomeId><gtr:partnerContribution>Provision of highly-purified peptides for the immunologicla readout of HIVconsv-specific responses in animals and humans</gtr:partnerContribution><gtr:piContribution>MRC-owned insert HIVconsv is being inserted into IAVI-owned vectors by IAVI for joint preclinical and clinical collaborative studies</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Amyloidosis Centre</gtr:department><gtr:description>Clinical trial HIV-CORE003 in London</gtr:description><gtr:id>098580DB-04CB-4F4E-9F67-BD4D8226B837</gtr:id><gtr:impact>Multidisciplinary collaboration, the anticipated start of recruitment is March 2013.</gtr:impact><gtr:outcomeId>baUYnaLn3Gt-1</gtr:outcomeId><gtr:partnerContribution>Execution of clinical the trial HIV-CORE003, serum amyloid component P-depleting drug CHPHC.</gtr:partnerContribution><gtr:piContribution>This an MRC DCS award to Prof Sir Mark Pepys, to which we are contributing know-how, GMP vaccines, immunological reagents and evaluation of immunogenicity output.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Los Alamos National Laboratory</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Design of 2nd generation tHIVconsvX vaccines</gtr:description><gtr:id>36AFE361-16DB-4696-AD4E-9E50CF80A262</gtr:id><gtr:impact>2nd generation vaccine - so far pre-clinical grade constructed

A joint Patent between UOXF/ISIS and LANL</gtr:impact><gtr:outcomeId>5460ae17c5cd42.31815345-1</gtr:outcomeId><gtr:partnerContribution>Designed the 2 mosaics used and helped to select the conserved regions oh the HIV -1 proteome</gtr:partnerContribution><gtr:piContribution>Computer design of the 2nd generation conserved T cell immunogens tHIVconsvX</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Clinical trial HIV-CORE 001, 002, 003, 004 and RIVER, BCN01, BCN02 and PEACHI-04 volunteers</gtr:description><gtr:id>9F2DF146-E5C3-4733-A151-DEF7A740B9BB</gtr:id><gtr:impact>Safety and immunogenicity data on the MVA.HIVconsv vaccine.</gtr:impact><gtr:outcomeId>awnqZmyaaag-2</gtr:outcomeId><gtr:partnerContribution>Lucy Dorrell will provide a cohort of HIV-1-infected patients and carry out clinical trial evaluating safety and immunogenicity the MVA.HIVconsv vaccine.</gtr:partnerContribution><gtr:piContribution>Providing GMP vaccines, expertise and input on trial design and immunological analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kenya AIDS Vaccine Initiative (KAVI)</gtr:collaboratingOrganisation><gtr:country>Kenya, Republic of</gtr:country><gtr:description>Clinical trial HIV-CORE004 in Nairobi</gtr:description><gtr:id>4903E8E9-4EB9-4689-B613-6DAF2B3D1C94</gtr:id><gtr:impact>Multidisciplinary, recruitment is planned to commence in March 2013.</gtr:impact><gtr:outcomeId>UyqiRncp7Hm-1</gtr:outcomeId><gtr:partnerContribution>Running of the clinical trial and primary safety and immunogenicity evaluations.</gtr:partnerContribution><gtr:piContribution>This is a EDCTP-funded clinical trial HIV-CORE004. We are providing know-how, GMP vaccines and immunological reagents and help with data analysis.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Assessment of tHIVconsvX-specific responses in HIV-positive patients</gtr:description><gtr:id>63DBAB84-C6F0-4527-8CC1-3328F9F0FAD8</gtr:id><gtr:impact>In progress</gtr:impact><gtr:outcomeId>54621124a3e949.30537513-1</gtr:outcomeId><gtr:partnerContribution>Testing of peptides in HIV-1-positive patients</gtr:partnerContribution><gtr:piContribution>Design and provision of tHIVconsvX peptides</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cornell University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Weill Cornell Medicine</gtr:department><gtr:description>Induction of HIV neutralizing antibodies</gtr:description><gtr:id>88AEB1DE-5F8F-4C48-A6D6-0CB11DEBCCA8</gtr:id><gtr:impact>Studies with BG505 uncleaved - Publication

Studies with BG505 SOSIP - In progress</gtr:impact><gtr:outcomeId>54620bc661cd03.33177083-1</gtr:outcomeId><gtr:partnerContribution>WCMC - provision or trimeric gp140 BG505 SOSIP protein immunogen
IAVI - proviion of gp120 HBG505 unlceaved immunogen
Sir Willima Dunn Schol of Pathology - quality control and research assays for characterisation of vector-expressed Ev immunogen
Meditox - rabbit immunization study</gtr:partnerContribution><gtr:piContribution>We are developing heterologous prime-boost immunisation regimen delivering a highly promising HIV Env BG505 uncleaved or as SOSIP for induction of HIV neutralising antibodies.

Also we are developing regimens for efficient induction of T cell and B cell responses in parallel.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>IrsiCaixa Institute for AIDS Research</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Clinical trial HIV-CORE 001, 002, 003, 004 and RIVER, BCN01, BCN02 and PEACHI-04 volunteers</gtr:description><gtr:id>FD904ADF-E9DD-49DA-9D17-A288D62D0131</gtr:id><gtr:impact>Safety and immunogenicity data on the MVA.HIVconsv vaccine.</gtr:impact><gtr:outcomeId>awnqZmyaaag-1</gtr:outcomeId><gtr:partnerContribution>Lucy Dorrell will provide a cohort of HIV-1-infected patients and carry out clinical trial evaluating safety and immunogenicity the MVA.HIVconsv vaccine.</gtr:partnerContribution><gtr:piContribution>Providing GMP vaccines, expertise and input on trial design and immunological analysis</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Recipharm</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>RecipharmCobra Biologics (formerly Cobra Biomanufacturing)</gtr:department><gtr:description>GMP manufacture of DNA vaccine pTH.HIVA</gtr:description><gtr:id>605819F7-DB04-4AAE-B0A6-0E69C128BEB4</gtr:id><gtr:impact>GMP products enable us to test novel vaccine concepts in humans 19770697, 19266489, 18812202, 18440674, 17250931, 17170430, 17013989, 16641265, 16176847</gtr:impact><gtr:outcomeId>FFF2F6DC734-1</gtr:outcomeId><gtr:partnerContribution>GMP products enable us to test novel vaccine concepts in humans</gtr:partnerContribution><gtr:piContribution>We designed and constructed an HIV-1-derived immunogene and the expression cassette, and used Cobra's Operator-Repressor Titration system for manufacture of plasmid with any antibiotic-resistance genes</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Okairos</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Construction and testing of ChAdV63.HIVconsv</gtr:description><gtr:id>098FAAEA-3D3A-4E9C-B6A2-31CD0B2625F2</gtr:id><gtr:impact>ChAdV63.HIVconsv has been highly immunogenic alone and in combination with other vaccine modalities. Construction has been completed, CHADV63.HIVconsv has been released to HIV-CORE002 trial, shelf-life stability tests and pre-clinical immunogenicity studies are on going</gtr:impact><gtr:outcomeId>69A2970E939-1</gtr:outcomeId><gtr:partnerContribution>Construction of ChAdV63.HIVconsv candidate vaccine against HIV-1 vectored by chimpanzee adenovirus 63.</gtr:partnerContribution><gtr:piContribution>We provided to Okairos an HIV-1-derived immunogen gene, which was inserted in chimpanzee adenovirus 63 by company Okairos. We have tested the immunogen expression and induction of HIV-1-specific T cells in mice and rhesus macaques. Okairos owns the ChAdV-63 vector.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Medicine</gtr:department><gtr:description>GMP manufacture ChAdV63.HIVconsv/QP release</gtr:description><gtr:id>4F15DB6A-B5AA-46EC-AD50-9743A273A1A0</gtr:id><gtr:impact>Manufacture of a clinical batch of ChAdV63.HIVconsv has been completed at the university's Clinical BioManufacturing Facility and it was released to HIV-CORE002 trial</gtr:impact><gtr:outcomeId>89EBD69C137-1</gtr:outcomeId><gtr:partnerContribution>Process Development for and GMP manufacture of ChAdV63.HIVconsv QP release to GMP of ChAdV63.HIVconsv QP release to two trials of two MVA.HIVconsv and ChAdV63.HIVconsv vaccines</gtr:partnerContribution><gtr:piContribution>Process Development for manufacture of ChAdV63.HIVconsv QP release of vaccines</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>IDT Biologika GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>GMP manufacture of MVA.HIVconsv/Qp release</gtr:description><gtr:id>F771DEFD-1DE1-4977-8AAD-39772B394336</gtr:id><gtr:impact>Clinical batch of MVA.HIVconsv vaccine has been manufactured and released to two trials HIV-CORE001 and HIV-CORE002. Shelf-life stability tests are on going.</gtr:impact><gtr:outcomeId>86A3631A135-1</gtr:outcomeId><gtr:partnerContribution>GMP manufacture of MVA.HIVconsv vaccine and QP release to GMP</gtr:partnerContribution><gtr:piContribution>Manufacture of GMP MVA.HIVconsv</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>NDM Podcast</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4A0688B4-B29D-4CDB-B2A1-A50434CD3570</gtr:id><gtr:impact>The podcast is available on the Univesity wensite.

Public understading.</gtr:impact><gtr:outcomeId>hZJmEWSkHTB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CFD9F1D0-7E7C-434C-BC4A-8B6528D67662</gtr:id><gtr:impact>Large audience

Publicity, awareness</gtr:impact><gtr:outcomeId>mDdoECsdhf1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Adjacent Governmant article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CDC94ED2-7540-474A-AD85-F555EBB8A269</gtr:id><gtr:impact>Articles describing the importance of our research

Invitations to do more</gtr:impact><gtr:outcomeId>546222988f2898.72220119</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Innovation Article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5907E566-B945-4179-9CF2-F2B4C62FF4A9</gtr:id><gtr:impact>Dissemination of science, research and technology

Many more requests from similar journals</gtr:impact><gtr:outcomeId>54622111af9f61.50184043</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>EDCTP Strategic Primer</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:fundingRef>SP.2011.41304.002</gtr:fundingRef><gtr:id>2CE8CFAB-938D-4AA0-A29A-4BADF2039751</gtr:id><gtr:outcomeId>gwCK25hT2kN</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1322832</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme grant</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1001757/1</gtr:fundingRef><gtr:id>C8C832A1-8C5C-477F-A05D-164569CCCA12</gtr:id><gtr:outcomeId>VGMwJuofEf80</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>IAVI post-doctoral fellowship</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>International AIDS Vaccine Initiative (IAVI)</gtr:fundingOrg><gtr:fundingRef>N/A</gtr:fundingRef><gtr:id>80552350-CD2A-4317-8A2B-BD01F3A019A9</gtr:id><gtr:outcomeId>jkZWhpNTTsH</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1031751</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DCS</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J008605/1</gtr:fundingRef><gtr:id>C908DCA2-4FAB-4179-B177-ED3D82EA33E0</gtr:id><gtr:outcomeId>fvdtzuK7343</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC RIVER DCS</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L00528X/1</gtr:fundingRef><gtr:id>FAF55532-BF29-4ADD-B387-344FBDFDE458</gtr:id><gtr:outcomeId>DoC4gAAqW31</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>FP7</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>305632</gtr:fundingRef><gtr:id>4A44D1BE-0453-43E4-9887-2C4897AF3D52</gtr:id><gtr:outcomeId>ZPLSWYV1VJ2</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>pTHr.HIVconsv, MVA.HIVconsv, ChAdV63.HIVconsv are HIV vaccine candidates that have been tested in 3 different prime-boost combinations in healthy HIV-negative volunteers. Safety evaluations have been completed. Immunogenicity analyses are ongoing. This work is funded by an MRC Experimental Medicine award for which I am a co-applicant.</gtr:description><gtr:id>C87FA69D-A03A-4634-BDF7-688E83F790D1</gtr:id><gtr:impact>Immunogenicity data have been published (PMID: 24166483). Other phase I studies are ongoing / planned and funding has been obtained.</gtr:impact><gtr:outcomeId>tLgbxxfNNCM</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>HIV-CORE 002 pTHr.HIVconsv, MVA.HIVconsv, ChAdV63.HIVconsv</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>http://clinicaltrials.gov/ct2/show/NCT01151319</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>HIVconsv is a universal T cell immunogen focusing T cells responses on the conserved, i.e. common regions of the HIV-1 proteome. HIVconsv was delivered by DNA, modified vaccinia virua Ankara (MVA) and chimpanzee adenovirus serotype 63 (ChAdV-63) to healthy uninfected individual in UK. It is prophylactic, not therapeutic vaccine.</gtr:description><gtr:id>DA566F39-9E3C-4998-9AAA-E7192A37FB28</gtr:id><gtr:impact>The first use of HIV vaccine based on conserved regions of the HIV-1 proteome to healthy individuals, the first use of ChAdV-63 for HIV vaccines, the first use of ChAdV-63 prime-MVA boost and DNA-ChAdV-63-MVA regimens for HIV in man</gtr:impact><gtr:outcomeId>Q7R21W5dTYi</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>HIV-CORE 002</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The first assessment of enhancement of DNA vaccination by serum amyloid component B depletion by CPHPC iv infusion in man
Primarily supported by an MRC award to Professor Sir Mark Pepys</gtr:description><gtr:id>7D62E402-7EB3-4743-BE2C-EEE57EE9919E</gtr:id><gtr:impact>Proof of concept trial</gtr:impact><gtr:outcomeId>iFzjR2EgqRR</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>HIV-CORE 003</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Assessment of decreasing latent HIV pool by reactivation and vaccination</gtr:description><gtr:id>77A16E67-EF9D-4F92-BFA0-4749B946198A</gtr:id><gtr:impact>Testing in process</gtr:impact><gtr:outcomeId>546228e46b00c5.03016183</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>RIVER</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>http://www.croiconference.org/sessions/viral-control-induced-hivconsv-vaccines-romidepsin-early-treated-individuals</gtr:description><gtr:id>4B8F685C-B62B-4D13-9FB9-7DE978A8D592</gtr:id><gtr:impact>Early times</gtr:impact><gtr:outcomeId>58c038cb4e8bf8.29111937</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>BCN 02 - ROMI</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>http://www.croiconference.org/sessions/viral-control-induced-hivconsv-vaccines-romidepsin-early-treated-individuals</gtr:url><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The first evaluation of the conserved region vaccines delivered by DNA (electroporated), MVA and HAdV-35 in healthy HIV-uninfected adults in Nairobi, Kenya
Prophylactic, not therapeutic vaccine
Trial is in not completed 
Mainly supported by EDCTP award</gtr:description><gtr:id>44631ADB-46B0-4E00-8D60-51E4769DD0BA</gtr:id><gtr:impact>The first test of these vaccine in Africa</gtr:impact><gtr:outcomeId>WK8TE3A72AV</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>HIV-CORE 004</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:ukcrnIsctnId>Ref no. PPB/ECCT/13/07/01/2013/(100) (Kenya regulator)</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We shall test novel potent T cell vaccines delivered in combination to safely induce anti-HCV and anti-HIV T cell immunity simultaneously in a single host.</gtr:description><gtr:id>202E851F-6AB9-43A0-B8BA-115603DB71DF</gtr:id><gtr:impact>Clinical trial is recruiting.</gtr:impact><gtr:outcomeId>54622aad7c6320.01232307</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PEACHI 04</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The first use of conserved region vaccine MVA.HIVconsv in HIV-infected individuals in UK
Primarily supported by a MRC award to Dr Lucy Dorrell</gtr:description><gtr:id>9626A6C0-FBD3-4C3B-9E54-FD0747D79C87</gtr:id><gtr:impact>The first use of conserved region vaccine in man</gtr:impact><gtr:outcomeId>tXNgaHgz9ob</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>HIV-CORE 001</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The first immunogenicity evaluation of ChAdV63.HIVconsv prime-MVA.HIVconsv boost vaccine regimen delivering conserved regions of the HIV-1 proteome in HIV-1-infected individuals early on HAART</gtr:description><gtr:id>529508DF-FFD3-4D82-8666-5EF09B499FDD</gtr:id><gtr:impact>The fist therapeutic use of this vaccine regimen in HIV-infected individuals</gtr:impact><gtr:outcomeId>MRKfKGWbeaD</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>BCN 01</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>New candidate HIV vaccine</gtr:description><gtr:id>EDFDF8C5-2EDA-4D60-94A6-4131EA43E2C4</gtr:id><gtr:impact>Interest of peers, new collaborations, new grant submission</gtr:impact><gtr:outcomeId>4B6626A9D18</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>3 GMP candidate HIV-1 vaccines</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2E5CE4D6-494E-479F-B56C-FFBD889EC31B</gtr:id><gtr:title>Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines.</gtr:title><gtr:parentPublicationTitle>Expert opinion on biological therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9888e0f37e7d1c89e61cdc32ed5605b0"><gtr:id>9888e0f37e7d1c89e61cdc32ed5605b0</gtr:id><gtr:otherNames>Hanke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2598</gtr:issn><gtr:outcomeId>doi_12588_014_885946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAF08355-9FA5-4694-B2FB-2407C29F757E</gtr:id><gtr:title>Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3441c03103165dcfb5bb79efb38b06ef"><gtr:id>3441c03103165dcfb5bb79efb38b06ef</gtr:id><gtr:otherNames>Ondondo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>56d18490c3d2e0.18719277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1801E35D-2253-4A89-AE5F-09548DC1F2C2</gtr:id><gtr:title>Preclinical development of BCG.HIVA, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity.</gtr:title><gtr:parentPublicationTitle>Human vaccines &amp; immunotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fc2a5e2b62a2df8a613fdb3b6454304"><gtr:id>5fc2a5e2b62a2df8a613fdb3b6454304</gtr:id><gtr:otherNames>Mahant A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2164-5515</gtr:issn><gtr:outcomeId>5a9d7e2b08e023.63055664</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA473990-3453-4910-AB22-1F0883CB4BEC</gtr:id><gtr:title>Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6dc8910324a5dc6c58b9fae087cba8e"><gtr:id>c6dc8910324a5dc6c58b9fae087cba8e</gtr:id><gtr:otherNames>Rosario M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>RTaadEBFUAN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F12AEC83-4E5E-4532-956A-77FA46ACB5AA</gtr:id><gtr:title>Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/215a458258dd460674f9cc98e1c2b628"><gtr:id>215a458258dd460674f9cc98e1c2b628</gtr:id><gtr:otherNames>Hancock G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>56d18492c3df64.59892738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1428766-C6B7-49B1-BCF4-40ED285276E3</gtr:id><gtr:title>Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: Mapping of CD8+ T Cell Epitopes</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/302ade6eef72f1f78249a8d74c749a76"><gtr:id>302ade6eef72f1f78249a8d74c749a76</gtr:id><gtr:otherNames>Borthwick N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5460aa6039f119.02364681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74055FD8-BDCE-47CC-B410-D0BC4D0BA704</gtr:id><gtr:title>A statistical approach to determining responses to individual peptides from pooled-peptide ELISpot data.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16b26d8a504fa824577d7c9a7ea4c286"><gtr:id>16b26d8a504fa824577d7c9a7ea4c286</gtr:id><gtr:otherNames>Str?m P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>585d6721bc8a44.65792738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D99B0EE6-B1F0-4BC4-8903-85390CD6DC3F</gtr:id><gtr:title>Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41cb177d0a6d4515f8687dec3eaae05d"><gtr:id>41cb177d0a6d4515f8687dec3eaae05d</gtr:id><gtr:otherNames>Naarding MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>doi_12588_013_11_021</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7B4E283-F372-433F-B9E0-7028C747A99D</gtr:id><gtr:title>Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10fdc3a18782fadea3984d32a070baa5"><gtr:id>10fdc3a18782fadea3984d32a070baa5</gtr:id><gtr:otherNames>Hayton EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_55f98598587ef5c7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBD1FF61-242C-4D50-B384-DFC4B6316225</gtr:id><gtr:title>Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd46411c37ebf6a7f879374f9fe427a2"><gtr:id>fd46411c37ebf6a7f879374f9fe427a2</gtr:id><gtr:otherNames>Clutton G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5460aaa67dd057.46960061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49851B2B-B80F-43D4-A0EC-3498B265920F</gtr:id><gtr:title>Evaluation of the Immunogenicity and Impact on the Latent HIV-1 Reservoir of an HIV Conserved Region Vaccine, MVA.HIVconsv, in HAART-treated Subjects</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76a77438793da366546ba3f51da666b2"><gtr:id>76a77438793da366546ba3f51da666b2</gtr:id><gtr:otherNames>Mor?n-L?pez S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5460aa361589f9.62672519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C775028-BC5A-43FC-8920-E9DA00E3C6AF</gtr:id><gtr:title>Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/302ade6eef72f1f78249a8d74c749a76"><gtr:id>302ade6eef72f1f78249a8d74c749a76</gtr:id><gtr:otherNames>Borthwick N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>pm_12588_28_24166483</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>594F729A-B092-45C3-9B17-C5E0280FA896</gtr:id><gtr:title>Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3441c03103165dcfb5bb79efb38b06ef"><gtr:id>3441c03103165dcfb5bb79efb38b06ef</gtr:id><gtr:otherNames>Ondondo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_12588_28_23831324</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D788343-B596-46AE-ABAF-2F8A964C4E19</gtr:id><gtr:title>Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/215a458258dd460674f9cc98e1c2b628"><gtr:id>215a458258dd460674f9cc98e1c2b628</gtr:id><gtr:otherNames>Hancock G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>5a9d74bd940914.04465631</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCB46F8F-3053-4CD5-B7EE-B79F9AFE883F</gtr:id><gtr:title>Control of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97f7291a65144b6159945ac5510fe4f1"><gtr:id>97f7291a65144b6159945ac5510fe4f1</gtr:id><gtr:otherNames>Ahmed T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>56d181799398b1.94299235</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69BD7F56-174F-4C6B-8047-185C11BA9A66</gtr:id><gtr:title>A Novel T-cell Vaccine Eliciting T-cell Specificities Associated with Control of HIV-1 In Humans Is Highly Immunogenic in Mice and Macaques</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92e29644a267ffb27cceb67604bc0126"><gtr:id>92e29644a267ffb27cceb67604bc0126</gtr:id><gtr:otherNames>Mothe B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5460aa11398035.30362313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE8CBDCF-427A-48B9-9567-9E64E247FB76</gtr:id><gtr:title>Dendritic cells enter lymph vessels by hyaluronan-mediated docking to the endothelial receptor LYVE-1.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4045ec99722c5d534bac690f76cfe482"><gtr:id>4045ec99722c5d534bac690f76cfe482</gtr:id><gtr:otherNames>Johnson LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>5a9d74bd06a026.47370927</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>482C87D1-CB81-4647-995F-9BF8F1908659</gtr:id><gtr:title>Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice.</gtr:title><gtr:parentPublicationTitle>Clinical and vaccine immunology : CVI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3441c03103165dcfb5bb79efb38b06ef"><gtr:id>3441c03103165dcfb5bb79efb38b06ef</gtr:id><gtr:otherNames>Ondondo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1556-679X</gtr:issn><gtr:outcomeId>5460aa86247605.59190414</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701669</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>